#1
|
|||
|
|||
Ìíîæåñòâåííàÿ ìèåëîìà
Çäðàâñòâóéòå, ìîåé òåòå, åé ñåé÷àñ 55 ëåò, â ñåíòÿáðå 2013 ã ïîñòàâèëè äèàãíîç ìíîæåñòâåííàÿ ìèåëîìà 3 B st., 2 êë.ãð.
Çà ýòî âðåìÿ îíà ïðîøëà 19 õèìèîòåðàïèé, ëå÷åíèå Âåëêåéäîì (áûë îòâåò íà ïðåïàðàò, íî ÷åðåç ïîë ãîäà ðåöèäèâ), çàòåì Ðåâëèìèä. Ïîñëåäíèé êóðñ õèìèîòåðàïèè 10.02.2017- 14.02.2017. Âèä: ïîëèõèìèîòåðàïèÿ. - Ìåòîä: öèòîñòàòè÷åñêàÿ òåðàïèÿ, ïî ñõåìå: âèíêðèñòèí 2ìã., èäàðóáèöèí 5ìã, äåêñàìåòàçîí 40 ìã. - Ñîïðîâîäèòåëüíàÿ òåðàïèÿ: îíäàíñåòðîí, îìåïðàçîë, èíôóçèîííàÿ òåðàïèÿ, ýòàìçèëàò, òðàìàäîë - Ãåìîñòèìóëèðóþùàÿ òåðàïèÿ, ýïîýòèí àëüôà 10 òûñ.Åä¹4 - Äâàæäû ïðîâåäåíû ñåàíñû ïëàçìàôåðåçà çàìåùåíèåì ÑÇÏ è ðàñòâîðà àëüáóìèíà. Ñîãëàñíî ðåøåíèþ ÂÊ áîëüíàÿ âûïèñàíà äëÿ ïðîâåäåíèÿ ïàëëèàòèâíîé ÕÒ â àìáóëàòîðíûõ óñëîâèÿõ ïîä íàáëþäåíèåì îíêîëîãà, òåðàïåâòà ïî ì/æèòåëüñòâà. Êëèíè÷åñêèé äèàãíîç: Ñ90.0 Ìíîæåñòâåííàÿ ìèåëîìà, ðåôðàêòåðíîñòü ê õèìèîòåðàïèè, ïðîãðåññèðóþùåå òå÷åíèå, III B st., II êë.ãð. Îñëîæíåíèÿ çàáîëåâàíèÿ: Ñèíäðîì ãèïåðâÿçêîñòè: íîñîâîå êðîâîòå÷åíèå. Îñòåîäåñòðóêòèâíûé ñèíäðîì. Áîëåâîé ñèíäðîì. Âòîðè÷íàÿ ïàíöèòîïåíèÿ. Àíåìè÷åñêèé ñèíäðîì ñðåäíåé òÿæåñòè. Áèîõèìè÷åñêîå èññëåäîâàíèå êðîâè îò 07.02.2017: îáùèé áåëîê - 136ã/ë Áåëîê áåòà-2-ìèêðîãëîáóëèí - 19768íã/ìë. Êðàòêèé àíàëèç 9 ïàðàìåòðîâ îò 13.02.2017: Ë - 3,56*109/ë; Ýð - 2,6*1012/ë; Hb - 79ã/ë, Òð - 75*109/ë Áèîõèìè÷åñêîå èññëåäîâàíèå êðîâè îò 13.02.2017: îáùèé áåëîê - 129ã/ë, ìî÷åâèíà - 4,1 ììîëü/ë, êðåàòèíèí - 69,3 ìêìîëü/ë. Áèîõèìè÷åñêîå èññëåäîâàíèå êðîâè îò 15.02.2017: îáùèé áåëîê - 114ã/ë, ìî÷åâèíà - 5 ììîëü/ë, êðåàòèíèí - 72,6 ìêìîëü/ë Êðàòêèé àíàëèç 9 ïàðàìåòðîâ îò 17.02.2017: Ë - 3,00*109/ë; Ýð - 2,7*1012/ë; Hb - 80ã/ë, Òð - 96*109/ë Ðåêîìåíäîâàíî ïðîâåäåíèå ïàëëèàòèâíîé ÕÒ â àìáóëàòîðíûõ óñëîâèÿõ ïî ñõåìå CD: - Öèêëîôîñôàìèä ïî 50ìã õ 1ð/ä ïåðîðàëüíî åæåäíåâíî ñ 1 ïî 21 äíè - Äåêñàìåòàçîí 20ìã Êàê ÿ ïîíèìàþ, åå îòïðàâèëè äîæèâàòü. Ïîìîãèòå ñîâåòîì, ÷òî ìû åùå ìîæåì ñäåëàòü? Ìîæåì ëè äîáèâàòüñÿ ëå÷åíèå Èìíîâèäîì? Ðåôíîò (Èíãàðîí) èñïîëüçóþò ïðè ìíîæåñòâåííîé ìèåëîìå? Åñëè áóäåì êóðñàìè äåëàòü ïëàçìàôåðåç - ïîìîæåò ïðîäëèòü æèçíü? Èëè Áåëîê áåòà-2-ìèêðîãëîáóëèí âñå ðàâíî áóäåò ðàñòè? |
#2
|
||||
|
||||
çàî÷íî íè÷åãî íåâîçìîæíî ïðåäóãàäàòü, ïóëüñ-òåðàïèÿ äåêñàìåòàçîíîì ìîæåò áûòü îïòèìàëüíîé ïðè öèòîïåíèè
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#3
|
|||
|
|||
Ñïàñèáî Dr.Vad çà ñòîëü áûñòðûé îòâåò. ß áû õîòåëà óçíàòü Âàøå ìíåíèå ïî ïîâîäó ïðåïàðàòà Èìíîâèä, ñ òàêèìè àíàëèçàìè êðîâè è ñ òàêîé ñòàäèåé áîëåçíè ýòîò ïðåïàðàò ìîæåò óëó÷øèòü êà÷åñòâî æèçíè è ïðîäëèòü åå? ß ïîíèìàþ ÷òî ýòî âñå èíäèâèäóàëüíî, íî ìû õâàòàåìñÿ çà ëþáóþ ñîëîìèíêó.
|
#4
|
|||
|
|||
È åùå õîòåëà óçíàòü, Âû ñëûøàëè ÷òî-íèáóäü î Ðåôíîò? Åãî öåëåñîîáðàçíî èñïîëüçîâàòü ïðè ìíîæåñòâåííîé ìèåëîìå?
|
#5
|
||||
|
||||
ìíå äàííûå ïðåïàðàòû íå çíàêîìû
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#6
|
|||
|
|||
ß áûëà íå ñîâñåì êîððåêòíà
- Èìíîâèä (Pomalidomide) â ÑØÀ çàðåãèñòðèðîâàí êàê POMALYST - Ðåôíîò - ôàêòîð íåêðîçà îïóõîëåé - òèìîçèí α-1 ðåêîìáèíàíòíûé |
#7
|
|||
|
|||
Ïðîòèâîïîêàçàíèÿ ê Ïîìàëèäîìèäó òÿæåëûå íàðóøåíèÿ ôóíêöèè ïî÷åê.
Áåëîê áåòà-2-ìèêðîãëîáóëèí - 19768íã/ìë. - ñâèäåòåëüñòâóåò î íàðóøåííîé ôóíêöèè ïî÷åê? |
|
#8
|
||||
|
||||
Ó âàñ åñòü äîñòóï ê äàííûì ïðåïàðàòàì? Íåò, íóæíî ñìîòðåòü êðåàòèíèí
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#9
|
|||
|
|||
Dr.Vad, ñïàñèáî Âàì çà òåðïåíèå.
Áèîõèìè÷åñêîå èññëåäîâàíèå êðîâè îò 07.02.2017: êðåàòèíèí - 84,7 ìêìîëü/ë 15.02.2017: êðåàòèíèí - 72,6 ìêìîëü/ë Ìû ñîáèðàåìñÿ ïîêóïàòü ñàì Ïîìàëèäîìèä, à íå ñåðòèôèöèðîâàííûé ïðåïàðàò. È îòïðàâèì çàÿâêó â ÐîñÌèíÇäðàâ, êòî çíàåò, ìîæåò è ïîñòàâÿò íà áþäæåò. Êàê Âû äóìàåòå, ñòîèò ïðîâîäèòü âûñîêîäîçíûå ñõåìû ñ ïëàòèíîé?  ýòîì ôåâðàëå òåòþ âûïèñàëè ñî ñëîâàìè: "Áóäèòå ëå÷èòüñÿ äîìà ñóõîé õèìèåé, ñèëüíàÿ õèìèÿ ïðè÷èíèò áîëüøå âðåäà". Íî ìû íå õîòèì ñäàâàòüñÿ è ïîêîðíî æäàòü ñìåðòè. |
#10
|
||||
|
||||
Åñëè Âû ìîæåòå îðãàíèçîâàòü ïëàçìàôåðåç (óäàëåíèå 2-3 ëèòðîâ ïëàçìû çà 1 ðàç ñ çàìåíîé àëüáóìèíîì/äîíîðñêîé ïëàçìû) ïëþñ ïóëüñ òåðàïèÿ äåêñàìåòàçîíîì, òî ó Âàøåé òåòè áûòü ìîæåò áóäåò âðåìÿ äîæäàòüñÿ, ïîêà Âû ÷òî-òî òàì êóïèòå èëè ÷òî-òî òàì êîìó-òî ïîñòàâÿò.
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#11
|
|||
|
|||
Êàê ÷àñòî ñëåäóåò äåëàòü ïðîöåäóðó ïëàçìàôåðåçà? Êàæäûå 2 íåäåëè ïî 2-4 ïðîöåäóðû ñ èíòåðâàëîì â ïàðó äíåé? Èëè êàæäóþ íåäåëþ?
|
#12
|
||||
|
||||
Ïðè çàìåíå 3 ëèòðîâ ïëàçìû êîëè÷åñòâî ïàòîëîãè÷. áåëêà ñíèæàåòñÿ íà òðåòü, öåëü ôåðåçà óäåðæàòü êîíöåíòðàöèþ áåëêà â êðîâè ìåíåå 100 ã/ë è ïðåïÿòñòâîâàòü ðàçâèòèþ ñèíäðîìà ïîâûø. âÿçêîñòè êðîâè, ïóëüñ-òåðàïèÿ ñíèæàåò ñèíòåç ïàòîë. áåëêà îïóõîë. êëåòêàìè
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#13
|
|||
|
|||
Íàì íàäî êîíòðîëèðîâàòü îáùèé áåëîê â êðîâè? Êàê ïîâûøàåòñÿ áîëüøå 100 äåëàòü ïëàçìàôåðåç?
|
#14
|
||||
|
||||
Ìîæíî âìåñòî äåêñàìåòàçîíà âîò òàêîé ðåæèì - åñëè åé ïîâåçåò è îíà îêàæåòñÿ â ÷èñëå (35%) îòâåòèâøèõ íà ëå÷åíèå (ïðîæèâåò ïåðâûé ìåñÿö), òî èìåþòñÿ øàíñû ïðîæèòü è ïîñëåäóþùèé ãîä-ïîëòîðà è äîæäàòüñÿ äð. ëå÷åíèÿ:
20 patients who had failed at least 1 chemotherapeutic regimen received methylprednisolone (2 g) intravenously 3 times weekly for 8 weeks. After 8 weeks, responders were placed on a maintenance phase of 2 g intravenously weekly with an 8-week reinduction at the time of relapse. 5 patients died within the first month of therapy. There were 2 complete responses, 2 objective responses and 3 minor responses. The median survival for all 20 patients was 2.2 months. Median survival for the 7 responders was 19 months, with a relapse-free survival of 15 months. 5 patients survived at least 16 months.
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#15
|
||||
|
||||
Ëè÷íî Âàì íè÷åãî íå íóæíî - Âàøåìó âðà÷ó, êîòîðûé áóäåò äåëàòü ôåðåç, ñëåäóåò èçìåðÿòü îá. áåëîê â êðîâè è óðîâåíü ïàòîë. áåëêà, êîãäà ïàò. áåëîê ñíèçèòñÿ íà ïîëîâèíó/äâå òðåòè è îá. áåëîê ñòàíåò ìåíåå 95-100, òî ï/ôåðåç âðåìåííî ïðåêðàùàåòñÿ è öèôðû áåëêà êîíòðîë. êàæäûå 10-15 äíåé.
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |